Related Experiment Videos
Ocular, systemic and antinuclear antibody changes with acebutolol.
The Journal of the Royal College of General Practitioners
|December 1, 1983
Summary
Acebutolol treatment in hypertensive patients showed increased tear secretion and antinuclear antibody development in some. However, no patients experienced severe side effects like oculomucocutaneous syndrome.
Area of Science:
- Cardiology
- Ophthalmology
- Rheumatology
Background:
- Hypertension management often involves beta-blockers like acebutolol.
- Understanding the side effect profile of antihypertensive medications is crucial for patient safety.
Purpose of the Study:
- To investigate the adverse effects of acebutolol in hypertensive patients.
- To assess the incidence of antinuclear antibody development and ophthalmic changes.
Main Methods:
- A cohort of 29 hypertensive patients was treated with acebutolol for 12 months.
- Antinuclear antibody titers and ophthalmic examinations were performed before and after treatment.
Main Results:
- 23% of patients developed an antinuclear antibody titer of >= 1/64.
- A statistically significant increase in tear secretion was observed after 12 months.
- One patient experienced mild psoriasis worsening; no cases of OMCS or SLE were reported.
Conclusions:
- Acebutolol may be associated with increased tear secretion and antinuclear antibody development.
- The drug appears safe regarding oculomucocutaneous syndrome and systemic lupus erythematosus.
- Long-term monitoring for specific side effects is warranted in patients on acebutolol.